In terms of speculation on another credit raise this year, it has been stated several times that the Kincell Bio sale of the GMP facility allows for imugene to extend their runway of all their trials into 2026.
This may of course change should there be some type of deal that sees us expand onto the Nasdaq, however that would most likely see a raise with institutional investors only.
If we were to see a CR this year or early 2025, without some promising news it would clearly decimate the shareprice and alienate many large retail investors.
DYOR opinion only
In terms of speculation on another credit raise this year, it...
-
- There are more pages in this discussion • 1,909 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $364.4M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 5.2¢ | 4.9¢ | $531.4K | 10.66M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 3429444 | 4.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.0¢ | 149299 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |